<?xml version="1.0" encoding="UTF-8"?>
<p class="p">An additional study to establish efficacy and safety of an aqueous extract of kava, a 3-week placebo-controlled double-blind, cross-over trial, specifically named as The Kava Anxiety Depression Spectrum Study (KADSS), was handled [
 <xref rid="B416-molecules-24-01364" ref-type="bibr" class="xref">416</xref>]. Sixty adult patients with 1 month or more of elevated GAD were prescribed daily five kava tablets (each containing 3.2 g, standardized to 50 mg of kavalactones) or placebo. Kava conferred a decrease of 11.4 points as compared to placebo on HAMA score. In addition, significant decrease in Beck Anxiety Inventory and Montgomeryâ€”Asberg Depression Rating Scale scores showed that it may also have antidepressant effects. In terms of safety concerns, extract did not resulted in serious adverse reactions.
</p>
